Celadon Pharmaceuticals has received certification to manufacture pharmaceutical-grade cannabis following government reforms five years ago.

The listed company said that its facility in Birmingham had been registered by the Medicines and Healthcare products Regulatory Agency (MHRA) under the “good manufacturing practice” regulations for its cannabis active pharmaceutical ingredient.

The company, quoted on Aim, the London Stock Exchange’s junior stock market, said it was understood to be the first registration of a UK pharmaceutical facility for both cultivating and manufacturing high tetrahydrocannabinol (THC) cannabis, which contains psychoactive properties, since the legalisation of medical cannabis in 2018.

Read the full story at The Times